12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway

Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway

Sudden loss of vision is one of the most alarming presentations in clinical medicine. In line with NICE clinical guidance and Royal College of Ophthalmologists pathways, a structured clinical approach begins with two fundamental questions: (1) Is the visual loss painless or painful? and (2) Is the deficit monocular or binocular? Monocular visual loss localises pathology to the anterior visual pathways anterior to the optic chiasm (globe, retina, or optic nerve).

---

Differential Diagnosis of Sudden Monocular Vision Loss

---

Sudden Painless Monocular Vision Loss: Retinal Vascular Emergencies

1. Central Retinal Artery Occlusion (CRAO)

Central retinal artery occlusion represents an acute ischemic infarction of the inner two-thirds of the retina, anatomically and pathophysiologically identical to an acute embolic cerebral stroke.

• Vascular Anatomy & Pathophysiology: The central retinal artery is the first intra-orbital branch of the ophthalmic artery (arising from the internal carotid artery). It is a true terminal end-artery with no collateral anastomoses (except in ~20% of the population who possess an accessory cilioretinal artery originating from the posterior ciliary circulation, which preserves a small island of central foveal vision). Sudden luminal occlusion triggers rapid, irreversible ischemic necrosis of retinal ganglion cells and the nerve fibre layer within 90 to 240 minutes.
• Aetiological Mechanisms:
  • Thromboembolism (~80%): Atheromatous plaque embolisation originating from the ipsilateral carotid artery bifurcation (cholesterol Hollenhorst plaques, calcific, or fibrin-platelet plugs) or cardiac sources (atrial fibrillation, left ventricular mural thrombus, infective endocarditis, valvular vegetations).
  • Arteritic CRAO (~10–15%): In patients aged >50 years, CRAO may be caused by Giant Cell Arteritis (GCA / Temporal Arteritis), where granulomatous vasculitis obliterates the vessel lumen. GCA represents an emergency requiring immediate high-dose intravenous steroids to protect the contralateral eye.
• Clinical Presentation: Catastrophic, sudden, painless, profound monocular visual loss occurring over seconds (often described as "a blind or dark shutter coming down"). Visual acuity is severely impaired, characteristically reduced to counting fingers, hand movements, or bare light perception.
• Examination & Fundoscopic Hallmarks:
  • Relative Afferent Pupillary Defect (RAPD): Pronounced and positive in the affected eye.
  • Milky-White Pale Retina: Diffuse ischemic intracellular edema of the ganglion cell layer causes the retina to lose its normal transparency, appearing milky-white, opaque, and ground-glass.
  • "Box-Carring" (Cattle-Trucking): Extreme arteriolar attenuation with visible segmentation and stasis of the erythrocyte columns within thread-like retinal arterioles.
  • The "Cherry-Red Spot" at the Fovea: A bright, vivid cherry-red circular spot at the fovea centralis. Pathophysiology: The fovea is the thinnest anatomical zone of the retina, devoid of ganglion cells and inner retinal layers; consequently, the underlying deep red, richly vascular choroid (supplied by the unaffected posterior ciliary arteries) shines brightly through the thin fovea, surrounded by the pale, edematous ischemic retina.
• Emergency Management Protocol:
  • CRAO is an ocular stroke. Refer immediately via the acute stroke pathway (or to an eye emergency service that works with it). The European Stroke Organisation (2021) and American Heart Association (2021) statements found that "conservative" measures (ocular massage, acetazolamide, anterior chamber paracentesis, carbogen or paper-bag rebreathing) have no proven benefit, and they are no longer recommended routinely. Where local protocols or trials allow, intravenous thrombolysis within 4.5 hours of onset is considered in eligible patients.
  • Stroke Pathway Evaluation: urgent carotid imaging (carotid endarterectomy is considered for symptomatic stenosis of 50–99% NASCET), 12-lead ECG and prolonged rhythm monitoring for atrial fibrillation, echocardiography, and secondary vascular prevention (antiplatelet therapy, high-intensity statin, blood pressure control).
  • Rule Out Giant Cell Arteritis: In any patient >50 years, immediately measure ESR and CRP; if GCA is suspected, administer high-dose IV methylprednisolone (or oral prednisolone 60 mg daily) immediately without waiting for temporal artery biopsy.

---

2. Central Retinal Vein Occlusion (CRVO)

Central retinal vein occlusion results from acute intraluminal thrombosis of the central retinal vein at or posterior to the lamina cribrosa.

• Risk Factors: Strongly associated with increasing age, systemic hypertension, diabetes mellitus, primary open-angle glaucoma, smoking, and hyperviscosity / hypercoagulable states (polycythaemia rubra vera, multiple myeloma, Waldenström's macroglobulinaemia, antiphospholipid syndrome).
• Pathophysiology & Presentation: Obstruction of venous outflow leads to massive hydrostatic pressure elevation, vascular engorgement, capillary breakdown, and extensive intraretinal extravasation of blood. Patients present with sudden or subacute, painless monocular visual impairment or "misty / foggy" blurring, characteristically noticed upon waking in the morning.
• Pathognomonic Fundoscopy: The "Blood and Thunder" Appearance:
  • Widespread, dramatic, extensive flame-shaped and blot intraretinal haemorrhages scattered across all four quadrants of the retina.
  • Markedly engorged, tortuous, dilated, and dark retinal veins.
  • Optic disc edema, hyperemia, and blurring of disc margins.
  • Cotton wool spots (fluffy white axoplasmic accumulations caused by nerve fibre layer micro-infarction).
• Complications & Specialist Management:
  • Macular Edema: The principal cause of chronic, permanent central visual loss in CRVO. Treated by ophthalmologists with regular intravitreal anti-VEGF injections (e.g. ranibizumab, aflibercept) or intravitreal dexamethasone implants (Ozurdex).
  • "100-Day Glaucoma" (Neovascular Glaucoma): Severe ischemic CRVO triggers massive release of vascular endothelial growth factor (VEGF), inducing neovascularisation of the iris (rubeosis iridis) and iridocorneal drainage angle around 90–100 days post-occlusion. This causes catastrophic, intractable secondary angle-closure glaucoma, preventable via prompt panretinal photocoagulation (PRP) laser therapy.
  • Systemic Workup: Screen for and optimize hypertension, diabetes, and hyperlipidaemia; perform FBC, ESR, and serum protein electrophoresis.

---

3. Rhegmatogenous Retinal Detachment

Retinal detachment is defined as the separation of the neurosensory retina (containing rods and cones) from the underlying retinal pigment epithelium (RPE), depriving photoreceptors of metabolic oxygen and nutrient supply from the choriocapillaris.

• Classification & Pathogenesis:
  • Rhegmatogenous Detachment (~90%): The most common subtype. Vitreous liquefaction (synchysis) and posterior vitreous detachment (PVD) exert traction on the peripheral retina, producing a full-thickness retinal tear or break (rhegma). Fluid from the liquefied vitreous cavity dissects through the break into the potential subretinal space, peeling the neurosensory retina off the RPE.
  • Predisposing Factors: High myopia (elongated axial globe with peripheral retinal thinning), previous cataract surgery (pseudophakia), peripheral retinal lattice degeneration, and blunt ocular trauma.
  • Non-rhegmatogenous Types: Tractional (fibrovascular bands pulling retina off RPE in proliferative diabetic retinopathy) and Exudative/Serous (subretinal fluid accumulation without tears in severe malignant hypertension or choroidal tumours).
• The Classical Clinical Tetrad — The "4 Fs":
  1. Flashes of light (Photopsia): Mechanical vitreoretinal traction stimulating peripheral photoreceptors; typically prominent in the temporal field and in dim lighting.
  2. Floaters: A sudden shower or dense swarm of dark spots, webs, or "cobwebs" (representing condensation of vitreous collagen fibrils, micro-vascular haemorrhage, or released retinal pigment cells—Shafer's sign / "tobacco dust" in the anterior vitreous).
  3. Field Defect: A progressive, dense, dark shadow or "curtain / veil falling over the visual field", typically starting peripherally and steadily advancing centrally.
  4. Fall in Visual Acuity: Occurs when the detachment advances to involve the central fovea/macula.
• Fundoscopic Findings: The detached retina appears as an elevated, pale, corrugated, grey-white folded sheet that billows and undulates with ocular movements. Retinal blood vessels appear dark and tortuous as they drape over the undulating folds. The normal red reflex is absent or markedly altered.
• Emergency Management & The "Macula-On" Rule:
  • Immediate emergency same-day ophthalmological referral.
  • Place patient at strict bed rest, positioning the head so that gravity assists in keeping the detached retina in apposition against the RPE.
  • The Critical Prognostic Rule:
    • "Macula-On" Detachment (Macula still attached; visual acuity preserved): An absolute emergency requiring surgical repair within 24 hours. Successful immediate surgery prevents detachment of the fovea, preserving central reading vision.
    • "Macula-Off" Detachment (Macula already detached; central vision lost): Urgent surgery within several days; however, visual prognosis is guarded because photoreceptor apoptosis begins within hours of macular detachment.
  • Surgical Interventions: Pars plana vitrectomy (with gas or silicone oil tamponade), scleral buckling, pneumatic retinopexy, and barrier cryotherapy/laser photocoagulation.

---

4. Vitreous Haemorrhage

Vitreous haemorrhage represents extravasation of blood into the vitreous humour and the potential space between the vitreous and internal limiting membrane of the retina.

• Aetiology: Predominantly caused by proliferative diabetic retinopathy (neovascular vessels originating from the retina or optic disc are fragile, leaky, and easily rupture under vitreoretinal traction); retinal tears with avulsion of retinal vessels; posterior vitreous detachment; and ocular trauma.
• Clinical Presentation: Sudden, painless onset of a dense swarm or shower of dark floaters, black dots, or lines, followed rapidly by dense visual fog, clouding, or profound vision loss (patients describe "looking through red smoke, ink, or a dark haze").
• Examination: The red reflex is markedly diminished or completely absent. On direct and indirect ophthalmoscopy, dark reddish-black clouds or shadows obscure the underlying retinal architecture.
• Management: Urgent ophthalmology referral. Advise strict bed rest with head-of-bed elevation to 30–45 degrees (allows intra-vitreal blood to settle inferiorly by gravity, clearing the central visual axis). Perform urgent B-scan ocular ultrasonography to examine the posterior segment and rule out an occult underlying retinal tear or detachment concealed by the hemorrhage. Persistent non-clearing hemorrhage warrants pars plana vitrectomy.

---

Acute Painful Monocular Vision Loss: Optic Nerve Pathology

Optic Neuritis

Optic neuritis is an acute, immune-mediated inflammatory demyelination of the optic nerve (cranial nerve II).

• Systemic Association with Multiple Sclerosis (MS): Optic neuritis is the initial presenting clinical manifestation in ~20% of patients with Multiple Sclerosis, and >50% of patients presenting with an isolated episode of optic neuritis subsequently develop clinically definite MS within 15 years. Other associations include neuromyelitis optica spectrum disorder (NMOSD; anti-aquaporin-4 antibodies) and MOG-antibody-associated disease.
• Demographics: Young adults, predominantly females aged 20–40 years (female-to-male ratio ~3:1).
• Clinical Presentation:
  • Subacute Monocular Visual Impairment: Vision loss develops over hours to several days, reaching maximum functional nadir within 1–2 weeks, ranging from mild blurring to complete loss of light perception.
  • Peri-Orbital / Retro-Orbital Pain: Present in >90% of patients. A dull, aching pain localized behind the globe that is characteristically exacerbated by extraocular eye movements (caused by traction of the inflamed optic nerve sheath at the orbital apex where the sheaths of the superior and medial rectus muscles fuse with the optic nerve dural sheath).
  • Dyschromatopsia (Red Colour Desaturation): Profound impairment of colour vision disproportionate to visual acuity loss. Vibrant red objects appear dull, washed out, pale pink, or grey; testing red desaturation using a red bottle cap is an extraordinarily sensitive clinical bedside test.
  • Uhthoff's Phenomenon: Transient worsening of visual acuity triggered by an increase in core body temperature (exercise, hot bath/shower, fever), reflecting conduction block in demyelinated axons.
• Examination Findings:
  • Relative Afferent Pupillary Defect (RAPD / Marcus Gunn Pupil): Pathognomonic objective hallmark of unilateral optic neuropathy. Tested via the Swinging-Flashlight Test.
  • Fundoscopy: In ~65% of cases, the optic nerve inflammation is retrobulbar (retrobulbar neuritis), meaning the fundus and optic disc appear entirely normal (classical adage: "the patient sees nothing, and the doctor sees nothing"). In ~35% of cases (papillitis), the optic disc shows mild hyperaemia, edema, and blurred margins.

                    [ Swinging-Flashlight Test Protocol ]

     1. Light Shone into NORMAL Left Eye      2. Light Swung to DISEASED Right Eye
     ┌───────────────────────────────────┐    ┌───────────────────────────────────┐
     │  Both pupils briskly CONSTRICT   │    │    Both pupils PARADOXICALLY      │
     │  (Intact afferent signals via CN2 │    │             DILATE                │
     │  drive bilateral efferent CN3)    │    │  (Diseased CN2 sends weak signal; │
     │                                   │    │   midbrain perceives less light)  │
     └───────────────────────────────────┘    └───────────────────────────────────┘

• Investigation & Management:
  • Urgent Contrast-Enhanced MRI of Brain and Orbits: Diagnostic modality of choice. Demonstrates hyperintensity and gadolinium enhancement of the affected optic nerve, and screens for asymptomatic periventricular demyelinating white matter plaques (Dawson's fingers). The presence of ≥1 cerebral demyelinating lesion strongly stratifies a high 10-year risk of developing clinical MS.
  • Natural History & Prognosis: Spontaneous visual recovery begins within 2–4 weeks in >90% of patients, with gradual return of near-normal Snellen visual acuity over 6–12 months.
  • Pharmacological Treatment: High-dose Intravenous Methylprednisolone (1 g daily for 3 days) followed by an oral prednisolone taper. High-dose IV methylprednisolone significantly accelerates the speed of visual recovery, although it does not alter long-term final visual acuity at 1 year. Critical prescribing rule: Low-dose oral prednisolone monotherapy alone without prior IV methylprednisolone is contraindicated because historical trials proved it doubled the rate of recurrent optic neuritis.

---

Gradual Vision Loss

NHS Diabetic Eye Screening Programme: digital retinal photography for everyone with diabetes aged 12 and over, annually (every 2 years for people at low risk after two consecutive normal screens), and more often in pregnancy. Rapid tightening of glucose control can temporarily worsen retinopathy.

Hypertensive retinopathy ranges from arteriolar narrowing and arteriovenous nipping to flame haemorrhages, cotton wool spots and papilloedema, which indicates accelerated (malignant) hypertension, a medical emergency.

---

Papilloedema & the Visual Pathway

Papilloedema is bilateral optic disc swelling from raised intracranial pressure: blurred disc margins, loss of spontaneous venous pulsation and haemorrhages, with an enlarged blind spot; acuity is preserved until late. It needs same-day neuroimaging (CT or MRI, with venography to exclude venous sinus thrombosis) before any lumbar puncture. Causes include tumours, haemorrhage, venous sinus thrombosis and idiopathic intracranial hypertension (section 7.5).